Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (21)

2024

  1. Incorporation of patient-reported outcomes into pharmacy and dermatology departments, in psoriasis and atopic dermatitis patients, as a tool to improve the healthcare quality and health outcomes

    Journal of Healthcare Quality Research, Vol. 39, Núm. 1, pp. 13-22

2021

  1. Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price

    Reumatologia Clinica, Vol. 17, Núm. 6, pp. 335-342

  2. Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study

    Pulmonary Pharmacology and Therapeutics, Vol. 69

  3. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer

    International Journal of Clinical Pharmacy, Vol. 43, Núm. 4, pp. 893-899

  4. The role of the pharmacist within an immune-mediated inflammatory disease unit: Results of a survey of healthcare providers and patients

    Farmacia Hospitalaria, Vol. 45, Núm. 6, pp. 305-316

2019

  1. Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 367-372

  2. Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 43, Núm. 1, pp. 24-30

2018

  1. Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price

    International Journal of Clinical Pharmacy, Vol. 40, Núm. 6, pp. 1528-1538

2011

  1. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Núm. 4, pp. 457-477

2008

  1. Combinación de métodos directos e indirectos de medición de la adherencia en pacientes VIH: Factores relacionados con la adherencia

    Atencion Farmaceutica, Vol. 10, Núm. 4, pp. 214-221

  2. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 6, pp. 1174-1180

2007

  1. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 7, pp. 879-885

  2. Drug interactions of tipranavir, a new HIV protease inhibitor.

    Drug metabolism letters, Vol. 1, Núm. 1, pp. 81-84

2005

  1. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations

    AIDS Research and Human Retroviruses, Vol. 21, Núm. 6, pp. 555-559

  2. Clinical benefit of interventions driven by therapeutic drug monitoring

    HIV Medicine, Vol. 6, Núm. 5, pp. 360-365

2004

  1. Higher efavirertz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations

    AIDS, Vol. 18, Núm. 15, pp. 2091-2094

  2. Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection

    AIDS Research and Human Retroviruses, Vol. 20, Núm. 7, pp. 698-700

  3. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient

    AIDS Research and Human Retroviruses, Vol. 20, Núm. 3, pp. 275-278

  4. Predictors of virological response to Atazanavir in protease inhibitor-experienced patients

    HIV Clinical Trials, Vol. 5, Núm. 4, pp. 201-205

2003

  1. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 17, Núm. 7, pp. 1023-1028